

EMA/73054/2021

European Medicines Agency decision P/0098/2021

of 19 March 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3) (EMA-002821-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0098/2021

of 19 March 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3) (EMA-002821-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by GlaxoSmithKline Biologicals SA on 4 June 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3), powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3), powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3), powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to GlaxoSmithKline Biologicals SA, rue de l'Institut, 89, 1330 – Rixensart, Belgium.

EMA/PDCO/579695/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002821-PIP01-20

Scope of the application

Active substance(s):

Respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3)

Condition(s):

Prevention of respiratory syncytial virus-associated lower respiratory tract illness through maternal immunisation

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

GlaxoSmithKline Biologicals SA

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GlaxoSmithKline Biologicals SA submitted for agreement to the European Medicines Agency on 4 June 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 September 2020.

Supplementary information was provided by the applicant on 23 October 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Prevention of respiratory syncytial virus (RSV) -associated lower respiratory tract illness through maternal immunisation

The waiver applies to:

- all subset of the male paediatric population from birth to less than 18 years of age;
- the female paediatric population from birth to less than 9 years of age;
- powder and solvent for solution for injection, intramuscular use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

2. Paediatric investigation plan

2.1. Condition:

Prevention of respiratory syncytial virus (RSV) -associated lower respiratory tract illness through maternal immunisation

2.1.1. Indication(s) targeted by the PIP

Active immunisation of pregnant women during the second and third trimester of pregnancy to prevent respiratory syncytial virus (RSV)-associated lower respiratory tract illness (LRTI) in infants

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Female adolescents from 9 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	2	Study 1 (RSV MAT-012) Randomised double-blind study to assess the reactogenicity, safety and immunogenicity of RSVPreF3 in pregnant adolescents from 15 years to less than 18 years of age (and adult women) to prevent RSV-infection in their offspring.

		Study 2 (RSV MAT-039) Randomised open-label active vaccine-controlled crossover study to assess the reactogenicity, safety and immunogenicity of RSVPreF3 in non-pregnant children and adolescents from 9 years to less than 18 years of age and in non-pregnant adult women.
Extrapolation, modelling and simulation studies	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes